Skip to main content

Peer Review reports

From: Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain – A GEICO study

Original Submission
10 Jun 2022 Submitted Original manuscript
18 Jul 2022 Reviewed Reviewer Report - Mafalda Jesus
20 Jul 2022 Reviewed Reviewer Report
31 Aug 2022 Reviewed Reviewer Report - Robert Póka
30 Sep 2022 Author responded Author comments - Alfonso Yubero
Resubmission - Version 2
30 Sep 2022 Submitted Manuscript version 2
8 Oct 2022 Reviewed Reviewer Report - Mafalda Jesus
Resubmission - Version 3
Submitted Manuscript version 3
Publishing
17 Oct 2022 Editorially accepted
8 Nov 2022 Article published 10.1186/s12885-022-10191-5

You can find further information about peer review here.

Back to article page